Thermo Fisher Expands Drug Development Capabilities with New…

Event summary

Thermo Fisher Scientific introduced OSD Express, a defined solution to accelerate oral solid dose development.
The company expanded small molecule capabilities through a collaboration with AustinPx, leveraging KinetiSol™ Technology.
Investments in tableting, laboratory, and packaging capabilities include new Gerteis technology for advanced dry granulation in France and Canada.
Steriles Express Solutions aim to reduce development timelines for sterile drug products, with Phase I/II material in 20 weeks and Phase III GMP batches in 26 weeks.
Thermo Fisher is applying AI and digital technologies to improve clinical development execution, including a 50% reduction in master informed consent form draft time.

The big picture

Thermo Fisher's strategic investments in drug development and manufacturing capabilities reflect the broader industry trend of consolidating and streamlining the complex pathways to commercialization. With annual revenue over $45 billion, the company is positioning itself to support pharmaceutical and biotechnology companies navigating the challenges of scaling programs and preparing for commercialization. The integration of AI and digital technologies underscores the shift towards data-driven decision-making in clinical development.

What we're watching

Execution Risk: Whether Thermo Fisher can sustain the pace of its strategic investments while maintaining operational efficiency.
Market Dynamics: How the expanded capabilities will position Thermo Fisher in the increasingly competitive drug development landscape.
Technological Integration: The effectiveness of AI and digital technologies in accelerating clinical development activities.